ORIGINAL ARTICLE

ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION

N. Abdulah , A. Dwifitriana Kouwagam, and A. Andina

N. Abdulah
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia. Email: nusratuddin@gmail.com

A. Dwifitriana Kouwagam
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia

and A. Andina
Department of Obstetrics and Gynecology Medical Faculty of Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital Makassar-Indonesia
Online First: June 03, 2014 | Cite this Article
Abdulah, N., Dwifitriana Kouwagam, A., Andina, a. 2014. ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION. Bali Medical Journal 3(2). DOI:10.15562/bmj.v3i2.78


Background: The age of nulliparous women has increased in developed countries and the 5-year survival rate for the late stage does not exceed 58%. Moreover, as more women are delaying child-bearing, preservation of fertility and reproductive function is a major concern when young women are counseled with regard to the effects of treatment for cervical cancer. Objective: To determine the effect of the combination chemotherapy on serum levels of Anti-Mullerian Hormone (AMH) and inhibin B. Methods: This study is a prospective cohort study in 16 cervical cancer patients aged 28-48 years who received Paclitaxel-Cisplatin chemotherapy. AMH and inhibin B levels were examined before and after third series chemotherapy. Statistical analysis used the Wilcoxon test with a level of significance selected at 0.05. Results: There is a significant decrease in median serum levels of AMH and inhibin B patients between before and after Paclitaxel–Cisplatin chemotherapy with p=0.000 (P <0.05). Similarly, a decrease in the median value of serum levels of AMH and inihibin B after Paclitaxel-Cisplatin chemotherapy in each series of chemotherapy was significant with p=0.000 (P <0.05). Conclusions: Serum levels of AMH and inhibin B in cervical cancer patients who received the combination chemotherapy decreased dramatically after 3 months of chemotherapy and the factors that contribute to the diminution is age.

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0